Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine).
Twenty patients with poor prognosis AML and four patients in the blastic phase of a myeloproliferative disorder were treated with two 'pulses' of therapy each consisting of two doses of high dose araC (separated by 12 h) followed by a single dose of mitoxantrone. The pulses were separated by 96 h. Amifostine was then administered tiw. The median age of the population was 68 years with 88% of patients having had either a prior MDS, MPD or toxic exposure. The acute leukemia of 58% of patients either entered a CR or reverted to preleukemic state. For patients under 70 years of age, treatment produced 62% CRs with a leukemia free decision marrow in 77%. For patients over 70 years the CR rate was 27% with 36% of patients having a leukemia free decision marrow.
Rush Cancer Institute, 1725 W. Harrison Street, Suite 809 PB I, Chicago, IL 60612, USA.
H D
HD
Preisler
P
P
Venugopal
S A
SA
Gregory
W
W
Hsu
J
J
Loew
S
S
Adler
S
S
Gezer
S
S
Creech
A
A
Galvez
D
D
Slivnick
T
T
Andric
R A
RA
Larson
A
A
Jajeh
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004999:Amifostine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D010865:Pilot Projects; D011379:Prognosis; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D016896:Treatment Outcome
D011837:Radiation-Protective Agents; D003561:Cytarabine; D008942:Mitoxantrone; D004999:Amifostine